SCHEMBL3297174

SCHEMBL3297174

C=CCNC(=S)Nc1cccc2cc3cccc4c3c(c12)C(=O)N(CCN(C)C)C4=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HEXA P06865 1/20 0.49
▸ HEXB P07686 1/20 0.49
▸ FTO Q9C0B1 3/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ PABPC1 P11940 1/20 0.45
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ POLB P06746 3/20 0.43
▸ NR1I2 O75469 1/20 0.43
▸ AHR P35869 1/20 0.43
▸ RAD52 P43351 1/20 0.43
▸ RCE1 Q9Y256 1/20 0.43
▸ CYP1A2 P05177 2/20 0.38
▸ TERT O14746 1/20 0.38
▸ TNNI3 P19429 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ STAT6 P42226 1/20 0.38
▸ TNNT2 P45379 1/20 0.38
▸ TNNC1 P63316 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3302695 0.90 HEXA (0.52) HEXAHEXBFTOCYP2D6PABPC1
SCHEMBL3298465 0.86 HEXA (0.47) HEXAHEXBFTOCYP2D6PABPC1
SCHEMBL3302233 0.85 HEXA (0.48) HEXAHEXBFTOCYP2D6PABPC1
SCHEMBL3298493 0.85 HEXA (0.48) HEXAHEXBFTOCYP2D6PABPC1
SCHEMBL3295851 0.84 ALDH1A1 (0.49) HEXAHEXBFTOCYP2D6PABPC1
SCHEMBL3295868 0.83 LMNA (0.49) HEXAHEXBFTOCYP2D6PABPC1
SCHEMBL3298903 0.83 HEXA (0.47) HEXAHEXBFTOCYP2D6PABPC1
SCHEMBL3294659 0.83 SMN1; SMN2 (0.48) HEXAHEXBFTOCYP2D6PABPC1
SCHEMBL13297973 0.83 HEXA (0.48) HEXAHEXBFTOCYP2D6PABPC1
SCHEMBL13297972 0.83 HEXA (0.57) HEXAHEXBFTOCYP2D6PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741337-B2 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom UNIBIOSCREEN S.A. (BE) 2010-06-22 — — US claimed
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom UNIBIOSCREEN S.A. (BE) 2008-11-27 — — US claimed
US-7741337-B2 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom UNIBIOSCREEN S.A. (BE) 2010-06-22 — — US disclosed
US-7741337-B2 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom UNIBIOSCREEN S.A. (BE) 2010-06-22 — — US disclosed
US-7741337-B2 Azonafide derivatives, methods for their production and pharmaceutical compositions therefrom UNIBIOSCREEN S.A. (BE) 2010-06-22 — — US disclosed
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom UNIBIOSCREEN S.A. (BE) 2008-11-27 — — US disclosed
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom UNIBIOSCREEN S.A. (BE) 2008-11-27 — — US disclosed
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom UNIBIOSCREEN S.A. (BE) 2008-11-27 — — US disclosed
WO-2007054292-A2 AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM UNIBIOSCREEN S.A. (BE) 2007-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080292585-A1 Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 HEXA 1944/4885HEXB 2802/4885FTO 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback